The Liquid Biopsy Company for Pets™ - PetDx®
Badge
Badge
Image
Badge
Badge

Early Cancer Detection in Dogs with a Simple Blood Draw

PetDx® invites you to learn more about liquid biopsy technology and our OncoK9® multi-cancer early detection (MCED) test for dogs.

OncoK9 Test Availability

Veterinarians in North America May Order Directly From PetDx or Through Our Partners
Antech
USA

USA Test Code: S14493

Canada

CANADA Test Code: CS14493

To learn more about ordering,
contact your Antech representative

(800) 872-1001
antechdiagnostics.com

IDEXX Reference Laboratories
USA

USA Test Code: 8972

Canada

CANADA Test Code: ONCOK9

To learn more about ordering,
contact your IDEXX representative

(800) 726-1212
idexx.com

OncoK9: Clinical Validation Study

Clinical validation of a next-generation sequencing-based multi-cancer early detection “liquid biopsy” blood test in over 1,000 dogs using an independent testing set: The CANcer Detection in Dogs (CANDiD) study

The international, multi-center clinical study demonstrated that OncoK9® – The Liquid Biopsy Test for Dogs can detect 30 different types of cancer with a simple blood draw. The CANDiD study included blood samples collected prospectively from more than 1,000 client-owned dogs at more than 40 clinical sites across the United States, Canada, Brazil, the Netherlands, France, and Hong Kong between 2019 and 2021.

Results of the CANDiD Study – the largest clinical validation study ever performed in veterinary cancer diagnostics – were recently published by PLOS ONE, a leading peer-reviewed journal.

6 Million New Cancer Cases Per Year in Dogs

Cancer is by far the single most common cause of death in adult dogs. Like humans, dogs have a 1 in 3 lifetime risk of getting cancer, and approximately 6 million dogs are newly diagnosed with cancer each year in the United States. Older dogs, and certain predisposed breeds, are at higher risk of developing cancer. Cancer is typically diagnosed in dogs at an advanced stage, when treatment options are limited, and chances of a cure are low. Each year, cancer cuts short the lives of many dogs who might have enjoyed many healthy years with their families had the disease been detected earlier.

Lifetime Risk of Cancer: 1 in 3 Dogs
Cancer is by Far the Biggest Threat to Dogs and the #1 Cause of Death

Cancer is a Disease of the Genome

Each cell in a dog's body contains billions of DNA "letters" that make up the dog's genome. Cancer develops as a result of the successive accumulation of genomic alterations (DNA mutations) over time. All cells release DNA fragments into the bloodstream, and DNA released from cancer cells contains unique genomic alterations that can be detected by liquid biopsy technology.

OncoK9

Early Cancer Detection in Dogs with a Simple Blood Draw

OncoK9® enables veterinarians to detect cancer in dogs with a simple blood draw. As a first-in-class multi-cancer early detection (MCED) test, OncoK9 employs cutting-edge genomic analysis that leverages next-generation sequencing (NGS) technology and proprietary bioinformatics algorithms empowering veterinarians to provide superior care to canine patients.

Simple blood draw

Simple
Blood Draw

Most cancer tests are either invasive (like a tissue biopsy) or require special equipment (like imaging). OncoK9 requires only a simple blood draw. The sample collection can take place during the same visit when the veterinarian prescribes the test.

Multi-cancer coverage

Multi-Cancer
Coverage

OncoK9 has demonstrated cancer signal detection in 30 different cancer types, including 8 of the most common cancers in dogs.

Cutting-edge technology

Cutting-Edge
Technology

OncoK9 interrogates millions of cell-free DNA fragments in each blood sample, using sophisticated next-generation sequencing technology and bioinformatics algorithms to detect genomic alterations associated with cancer.

Early detection

Early
Detection

By identifying cancer signal in cell-free DNA extracted from a blood sample, OncoK9 may allow for earlier detection of cancer, before the onset of clinical signs.

How the OncoK9 Liquid Biopsy Test Works

Step 1

Step 1

A blood sample is collected that contains cell-free DNA fragments released from healthy cells and cancer cells (if cancer is present).

Step 2

Step 2

A centrifuge is used to separate the blood sample into 3 components: plasma, buffy coat, and hematocrit.

Step 3

Step 3

Cell-free DNA is extracted from plasma and an amplified DNA library is prepared for sequencing.

Step 4

Step 4

Next-generation sequencing of the DNA library generates detailed data for analysis.

Step 5

Step 5

The lab uses proprietary bioinformatics algorithms to identify cancer-associated genomic alterations.

Step 6

Step 6

A clinical report is sent to the veterinarian indicating whether or not cancer signal has been detected.

All OncoK9 testing and interpretation steps are performed at the PetDx central laboratory in San Diego, California.

OncoK9: Intended Use

OncoK9 is a multi-cancer early detection (MCED) test for the detection and characterization of cancer-associated genomic alterations in DNA isolated from canine whole blood samples, using next-generation sequencing (NGS) technology. As with any laboratory test, OncoK9 results should be interpreted by a veterinarian in the context of each patient's medical history and clinical presentation. The test is available by prescription only.


OncoK9: Annual Screening

OncoK9 is recommended as an annual screening test for all dogs starting at 7 years of age and potentially at younger ages for dogs belonging to breeds that are predisposed to cancer.

Dogs 8 and Older Have a Higher Risk of Cancer
Certain Breeds Have a Higher Risk of Cancer at Younger Ages

OncoK9: Aid in Diagnosis

OncoK9 is recommended as an aid-in-diagnosis for dogs in which cancer is suspected based on clinical signs or other clinical findings.

Cancer Site is Suspected but Challenging to Access
Cancer is Suspected but Site is Not Clinically Evident

As an oncologist, I am excited about the ways in which the OncoK9 liquid biopsy test will benefit dogs, their families, and the veterinarians that manage their care.

Andi Flory
Andi Flory, DVM, DACVIM (Oncology)
PetDx Chief Medical Officer

PetDx in the Media

DeciBio

 |  Corporate Blog
Cancer Detection in Dogs: OncoK9 Liquid Biopsy and the CANDiD Study Q&A with Daniel Grosu of PetDx
View Media

GenomeWeb

 |  Science Publication
PetDx-led Team Clinically Validates Liquid Biopsy Test for Canine Cancers
View Media

Veterinary Practice News

 |  Veterinary Publication
Liquid biopsy test can detect 30 types of canine cancer, study shows
View Media

Wired

 |  Technology Publication
This Blood Test Detects Cancer in Dogs. But Do You Want to Know?
View Media

DVM360

 |  Veterinary Publication
Clinical validation study for pioneering early cancer detection test for dogs is published
View Media

Amy Shojai

 |  Blog
Dog Cancer Early Detection Test Receives Clinical Validation for 30 Canine Cancers
View Media

Vet Candy

 |  Veterinary Publication
Validation for early detection cancer screening for dogs published
View Media

Cheddar News

 |  Streaming News Channel
How PetDx Uses a Simple Blood Draw to Detect Cancer in Pets Early
View Media

dvm360

 |  Veterinary Publication
Clinical trial to evaluate OncoK9 liquid biopsy test for dogs
View Media

Nasdaq

 |  Stock Exchange Publication
IDEXX (IDXX) Collaborates With PetDx for Canine Cancer Test
View Media

dvm360

 |  Veterinary Publication
Multicancer detection in dogs with cell-free DNA
View Media

San Diego Business Journal

 |  Newspaper
Startups: Round to scale adoption of early-detection cancer test for K9s
View Media

GenomeWeb

 |  Science Publication
PetDx Raises $62M in Series B Round
View Media

Crunchbase

 |  Business Publication
PetDx Raises $62M To Get Canine Cancer-Detecting Tech To Vets Across The US
View Media

Illumina

 |  Corporate News Center
Early Cancer Detection for Dogs is Here
View Media

Join the Revolution in Early Cancer Detection for Dogs

If you are eager to incorporate breakthrough innovation into your veterinary practice, we would love to hear from you.

Be among the first to offer the OncoK9 multi-cancer early detection test to your canine patients.

Email Address *

First Name *

Last Name *

Practice Name *

Position/Role *

Zip Code *

Please input numbers only

Phone Number

Please input numbers only

Lead Source

Website

Web Form

Tactic

Target

Contact Level

* required field

Top